Table 3.
Sex hormone levels at baseline and year 1 and percentage changes in sex hormones in estrogen plus progestin and placebo group participants*
| Sex hormone | Estrogen plus progestin (n = 365) | Placebo (n = 331) | P |
|---|---|---|---|
| Baseline level | |||
| Total estradiol, pg/mL | 10.9 (7.8–14.8) | 10.6 (7.7–14.4) | .71 |
| Bioavailable estradiol, pg/mL | 7.0 (4.9–10.6) | 7.0 (4.8–10.0) | .87 |
| Estrone, pg/mL | 36.2 (27.6–48.4) | 36.2 (27.4–49.9) | .99 |
| Estrone sulfate, ng/mL | 0.77 (0.56–1.09) | 0.77 (0.56–1.03) | .76 |
| Total testosterone, ng/dL | 24.0 (17.8–33.5) | 23.8 (17.8–33.8) | .81 |
| Bioavailable testosterone, ng/dL | 12.3 (8.6–17.3) | 12.5 (9.1–16.7) | .73 |
| Progesterone, pg/mL | 61.0 (43.5–85.5) | 60.8 (40.1–84.9) | .69 |
| SHBG, ng/dL | 40.7 (28.3–57.1) | 41.3 (29.4–54.9) | .93 |
| Year 1 level | |||
| Total estradiol, pg/mL | 23.2 (15.0–32.0) | 9.1 (6.3–13.5) | <.0001 |
| Bioavailable estradiol, pg/mL | 10.1 (6.6–14.3) | 6.0 (4.0–9.4) | <.0001 |
| Estrone, pg/mL | 124.4 (72.6–185.5) | 34.5 (25.6–50.4) | <.0001 |
| Estrone sulfate, ng/mL | 1.98 (1.18–2.74) | 0.74 (0.53–0.96) | <.0001 |
| SHBG, ng/dL | 98.1 (64.7–141.0) | 41.5 (29.8–57.3) | <.0001 |
| Baseline to Year 1 percentage change | |||
| Total estradiol | 101.1 (17.9–217.4) | −13.5 (−35.3 to 14.4) | <.0001 |
| Bioavailable estradiol | 35.5 (–8.1–106.9) | −12.8 (−37.1 to 12.4) | <.0001 |
| Estrone | 228.2 (72.6–423.6) | −4.8 (−22.7 to 21.7) | <.0001 |
| Estrone sulfate | 132.4 (35.1–262.6) | −11.0 (−29.0 to 13.9) | <.0001 |
| SHBG | 133.6 (61.3–227.1) | 3.3 (−12.8 to 21.0) | <.0001 |
* Results were obtained using conditional logistic regression models. All statistical tests were two-sided. Data are median (interquartile range). SHBG = sex hormone–binding globulin.